The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides

Biomaterials

Volumn 23, Issue 2, 2002, Pages 321-342

  Chirila, Traian V ^a   Rakoczy, Piroska E ^a   Garrett, Kerryn L ^a   Lou, Xia ^a   Constable, Ian J ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antisense oligodeoxynucleotides; Antisense strategy; Charged polymers; Drug delivery; Endocytosis; Neutral polymers

Indexed keywords

CELL MEMBRANES; MACROMOLECULES; OLIGOMERS;

ANTISENES STRATEGY;

POLYMERS;

ANTISENSE OLIGODEOXYNUCLEOTIDE; COPOLYMER; CYCLODEXTRIN DERIVATIVE; DENDRIMER; GLATIRAMER; LACTONE DERIVATIVE; LIPOSOME; MACROGOL; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; NUCLEOCAPSID PROTEIN; NUCLEOTIDE; OLIGODEOXYNUCLEOTIDE; PEPTIDE; POLYANION; POLYCATION; POLYETHYLENEIMINE; POLYMER; POLYNUCLEOTIDE; POLYPEPTIDE; SYNTHETIC PEPTIDE; VIRUS PROTEIN;

COMPLEX FORMATION; DRUG DELIVERY SYSTEM; ENCAPSULATION; ENDOCYTOSIS; ENDOSOME; HYDROGEL; PRIORITY JOURNAL; REVIEW; SYNTHESIS;

ANIMALS; DRUG CARRIERS; OLIGONUCLEOTIDES, ANTISENSE; POLYMERS;

EID: 0036131650     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0142-9612(01)00125-9     Document Type: Review

References (210)

1. Prospects for human gene therapy
2. Progress toward human gene therapy
3. Altering the genome by homologous recombination
4. The new frontier; gene and oligonucleotide therapy
5. Gene therapy - promises, problems and prospects
6. Overcoming the obstacles to gene therapy
7. Therapeutic gene targeting
8. Facilitating oligonucleotide delivery; helping antisense deliver on its promise
9. Antisense technology; selection and delivery of optimally acting antisense oligonucleotides
10. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide
11. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide
12. Inhibition of thymidine kinase gene expression by anti-sense RNA; a molecular approach to genetic analysis
13. Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA
14. Antisense oligonucleotides; a new therapeutic approach
15. Antisense pharmacodynamics; critical issues in the transport and delivery of antisense oligonucleotides
16. Non-viral gene therapy
17. Nonviral gene therapy; the promise of genes as pharmaceutical products
18. Polymers in gene therapy
19. Nonviral strategies for gene therapy
20. Antisense strategies in cell and developmental biology
21. Antisense oligonucleotides; a new therapeutic principle
22. Antisense oligonucleotides
23. Therapeutic applications of oligonucleotides
24. Artificial regulation of gene expression by complementary oligonucleotides - an overview
25. Antisense oligonucleotides
26. Progress in antisense therapeutics
27. Structural gene identification and mapping by DNA mRNA hybrid-arrested cell-free translation
28. Antisense techniques; an overview
29. Cell delivery and mechanisms of action of antisense oligonucleotides
30. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents
31. Disrupting the flow of genetic information with antisense oligodeoxynucleotides; research and therapeutic applications
32. Development of targeted delivery systems for nucleic acid drugs
33. Antisense oligonucleotides as therapeutic agents
34. Therapeutic potential and mechanism of action of oligonucleotides and ribozymes
35. To cleave or not to cleave; ribozymes and antisense
36. Endocytosis; an overview
37. Inhibition of replication and expression of human T-cell lymphotrophic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA
38. Characterization of oligonucleotide transport into living cells
39. Pharmaceutical aspects of the biological stability and membrane transport characteristics of antisense oligonucleotides
40. As nature intended? The uptake of DNA and oligonucleotides by eukaryotic cells
41. Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation
42. Cellular uptake, distribution and metabolism of phosphorothioate, phosphodiester, and methylphosphonate oligonucleotides
43. Cellular internalization of oligodeoxynucleotides
44. In vivo pharmacokinetics of oligonucleotides following administration by different routes
45. Liposomes as a carrier for intracellular delivery of antisense oligonucleotides; a real or magic bullet?
46. Oligonucleotide biological activity; relationship to the cell cycle and nuclear transport
47. Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes
48. Oligonucleotide delivery; a cellular prospective
49. Function of c-mos proto-oncogene product in meiotic maturation in Xenopus oocytes
50. Role of matrix protein in cytopathogenesis of vesicular stomatitis virus
51. Inhibition of human immunodeficiency virus type-1 env expression by C-5 propyne oligonucleotides specific for rev-response element stem-loop V
52. Requirement of N-terminal amino acid residues of gp41 for human immunodeficiency virus type 1-mediated cell fusion
53. cAMP response element-binding protein in the amygdala is required for long-but not short-term conditioned taste aversion memory
54. Electroporation of synthetic oligonucleotides; a novel technique for ex vivo bone marrow purging
55. Retrovirally transduced antisense sequences stably suppress P210 BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines
56. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia
57. In vivo transfer efficiency of antisense oilgonucleotides into the myocardium using HVJ-liposome method
58. HVJ (Sendai virus)-cationic liposomes; a novel and potentially effective liposome-mediated technique for gene transfer to the airway epithelium
59. Liposomes as a drug delivery system for antisense oligonucleotides
60. Use of cationic lipids to enhance the biological activity of antisense oilgonucleotides
61. Liposomes as a delivery system for antisense and ribozyme compounds
62. Intracellular delivery of oligonucleotides with cationic liposomes
63. The delivery of oilgonucleotides using pH sensitive liposomes
64. Liposomal delivery of oligodeoxynucleotides
65. 3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid
66. Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system
67. In vivo delivery of phosphorothioate oligonucleotides into murine retina
68. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus
69. Intravitreal administration of antisense oligonucleotides; potential of liposomal delivery
70. Limitations of cationic liposomes for antisense oligonucleotide delivery in vivo
71. Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells
72. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines
73. Gene inhibition using antisense oligodeoxynucleotides
74. Lipofectin; a highly efficient, lipid-mediated DNA-transfection procedure
75. Combination between different proteins and between proteins and yeast nucleic acid
76. Studies on infection with Bacillus anthracis. IV. Preparation and characterization of an anthracidal substance from various animal tissues
77. Studies on infection with Bacillus anthracis. VII. A comparison of the antibacterial effects of calf thymus histone and a quaternary ammonium cationic detergent on B. anthracis
78. Agglutination of red cells by synthetic lysine polypeptides
79. Inhibitory effect of synthetic lysine polypeptides on growth of influenza virus in embryonated eggs
80. The inhibition of tobacco mosaic virus by synthetic lysine polypeptides
81. The combination of lysine polypeptides with tobacco mosaic virus
82. The agglutination and growth inhibition of bacteria by lysine polypeptides
83. The action of some water-soluble poly-α-amino acids on bacteria
84. Interaction of basic polyamino acids with the red blood cell. I. Combination of polylysine with single cells
85. Interactions of basic polyelectrolytes with the red blood cell. II. Agglutination of red blood cells by polymeric bases
86. An agar cell-suspension plaque assay for isolated viral RNA
87. The effect of polycations on the interaction of viral RNA with mammalian cells; studies on the infectivity of single- and double-stranded poliovirus RNA
88. Plaque assay for poliovirus and poliovirus specific RNAs
89. Influence of polycations on the interaction between poliovirus multistranded ribonucleic acid and HeLa cells
90. Infection of tobacco mesophyll protoplats by tobacco mosaic virus
91. Effect of DEAE-dextran on production of interferon induced by synthetic double-stranded RNA in L cell cultures
92. Cell interaction with a synthetic polynucleotide and interferon production in vitro
93. Interferon induction by single-stranded polynucleotides modified with polybases
94. Binding of basic proteins to DNA
95. Interaction of poly-L-lysine and nucleic acids
96. Template properties of DNA-polypeptide complexes
97. The preferential interactions of polylysine and polyarginine with specific base sequences in DNA
98. Model nucleoprotein complexes; studies on the interaction of cationic homopolypeptides with DNA
99. Helix-coil transition in nucleoprotein-chromatin structure
100. Histones and basic polyamino acids stimulate the uptake of albumin by tumor cells in culture
101. A membrane effect of basic polymers dependent on molecular size
102. Uptake of protein by mammalian cells; an underdeveloped area
103. Conjugation of poly-L-lysine to albumin and horseradish peroxidase; a novel method of enhancing the cellular uptake of proteins
104. Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells
105. Poly(L-lysine) has different membrane transport and drug-carrier properties when complexed with heparin
106. Uptake of polynucleotides by mammalian cells. XIV. Stimulation of the uptake of polynucleotides by poly(L-lysine)
107. 4-poly(L-lysine) conjugates in intact cells
108. n analogues; synthesis and biological activity
109. Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site
110. Antiviral activity of conjugates between poly(L-lysine) and synthetic oligodeoxyribonucleotides
111. Antiviral activity and possible mechanisms of action of oligonucleotides-poly(L-lysine) conjugates targeted to vesicular stomatitis virus mRNA and genomic mRNA
112. Biological activity of oligonucleotide-poly(L-lysine) conjugates; mechanism of cell uptake
113. Inhibition of human immunodeficiency virus type 1-mediated cytopathic effects by poly(L-lysine)-conjugated synthetic antisense oligodeoxyribonucleotides
114. Sequence-specific activity of antisense oligonucleotides conjugated to poly(L-lysine) carriers
115. Antisense drug delivery through the blood-brain barrier
116. Oligonucleotide-poly-L-ornithine conjugates; binding to complementary DNA and RNA
117. Anti-proliferative effects of unmodified antisense oligodeoxynucleotides targeted against c-raf mRNA; use of poly(lysine/serine) copolymers or cationic lipopolyamines
118. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system
119. Receptor-mediated gene delivery and expression in vivo
120. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides
121. Enhanced resistance to nuclease degradation of nucleic acids complexed to asialoglycoprotein-polylysine carriers
122. Targeted delivery of antisense oligonucleotides by molecular conjugates
123. Antisense DNA delivery in vivo; liver targeting by receptor-mediated uptake
124. Targeted antisense modulation of inflammatory cytokine receptors
125. Covalent protein-oligonucleotide conjugates for efficient delivery of antisense molecules
126. Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides
127. A new non-viral DNA delivery vector; the terplex system
128. Terplex system for delivery of DNA and oligonucleotides
129. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide
130. Cytosolic and nuclear delivery of oligonucleotides mediated by an amphiphilic anionic peptide
131. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells
132. Peptide-oligonucleotide phosphorothioate conjugates with membrane translocation and nuclear localization properties
133. DNA complexes with polycations for the delivery of genetic material into cell
134. Interpolyelectrolyte complexes for gene delivery; polymer aspects of transfection activity
135. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture
136. In vitro gene delivery by degraded polyamidoamine dendrimers
137. ® PAMAM dendrimers; a novel synthetic vector for the transfection of DNA into mammalian cells
138. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers
139. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers
140. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery
141. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo; polyethylenimine
142. Polyethylenimine but not cationic lipid improves antisense activity of 3′-capped phosphodiester oligonucleotides
143. Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery
144. Water-soluble block polycations as carriers for oligonucleotide delivery
145. Cationic block copolymers as self-assembling vectors for gene delivery
146. Spontaneous formation of polyion complex micelles with narrow distribution from antisense oligonucleotide and cationic block copolymers in physiological saline
147. Self-assembly of polyamine-poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides
148. Amphiphysin I antisense oligonucleotides inhibit neurite outgrowth in cultured hippocampal neurons
149. Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides
150. Cationic polystyrene nanoparticles; preparation and characterization of a model drug carrier system for antisense oligonucleotides
151. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides
152. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylates nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice
153. An approach for new anticancer drugs; oncogene-targeted antisense DNA
154. Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake
155. Antisense effects of cholesterol-oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate) nanoparticles
156. Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice
157. Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligonucleotides
158. c-myc in vasculoproliferative disease
159. Liposomes dispersed within a thermosensitive gel; a new dosage form for ocular delivery of oligonucleotides
160. Poly(1-vinyl-2-pyrrolidinone) hydrogels as vitreous substitutes; histopathological evaluation in the animal eye
161. Crosslinked poly(1-vinyl-2-pyrrolidinone) as a vitreous substitute
162. Polymers of 1-vinyl-2-pyrrolidinone as potential vitreous substitutes; physical selection
163. Biodegradation in vitro and retention in the rabbit eye of crosslinked poly(1-vinyl-2-pyrrolidinone) hydrogel as a vitreous substitute
164. Poly(1-vinyl-2-pyrrolidinone) hydrogels as vitreous substitutes; a rheological study
165. The use of hydrophilic polymers as artificial vitreous
166. In vitro cytotoxicity assay of synthetic hydrogels as potential vitreous substitutes
167. Effect of crosslinked poly(1-vinyl-2-pyrrolidinone) gels on cell growth in static cell cultures
168. Biodegradable poly(L-lactic acid) matrices for the sustained delivery of antisense oligonucleotides
169. Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres
170. Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides; characterization of P(LA-GA) copolymer microspheres in vitro
171. Inhibition of smooth muscle cell growth in vitro by an antisense oligodeoxynucleotide released from poly(DL-lactic-co-glycolic acid) microparticles
172. Release behavior of poly(lactic acid-co-glycolic acid) implants containing phosphorothioate oligodeoxynucleotide
173. Triple helix fromation at distant sites; hybrid oligonucleotides containing a polymeric linker
174. Activity of hammerhead ribozymes containing non-nucleotidic linkers
175. Structural optimization of non-nucleotide loop replacements for duplex and triplex DNAs
176. Synthesis of 3′-PEG-modified oligonucleotides on PS-PEG tentacle polymers
177. New solid-phase approach to obtain 3′-derivatized oligonucleotides
178. Characterization of oligodeoxyribonucleotide-polyethylene glycol conjugates by electrospray mass spectrometry
179. Antibacterial activity and inhibition of protein synthesis in Escherichia coli by antisense DNA analogs
180. Synhthesis and properties of oligodeoxyribonucleotide-polyethylene glycol conjugates
181. Stability, specific binding activity, and plasma concentration in mice of an oligodeoxynucleotide modified at 5′-terminal with poly(ethylene glycol)
182. Polyethylene glycol. A high-efficiency liquid phase (HELP) for the large-scale synthesis of the oligonucleotides
183. Synthesis and characterization of high-molecular mass polyethylene glycol-conjugated oligonucleotides
184. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia
185. Evaluation of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates as targetable drug carriers. 1. Binding, pinocytic uptake and intracellular distribution of transferrin and anti-transferrin receptor antibody conjugates
186. Release of macromolecules and daunomycin from hydrophilic gels containing enzymatically degradable bonds
187. Hydrogels for site-specific oral drug delivery; synthesis and characterization
188. Polymers for colon-specific drug delivery
189. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl)methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice
190. Effect of the chemical structure of N-(2-hydroxypropyl)methacrylamide copolymers on their ability to induce antibody formation in inbred strains of mice
191. Immunogenicity of N-(2-hydroxypropyl)methacrylamide
192. Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl)methacrylamide copolymers
193. Soluble, crosslinked N-(2-hydroxypropyl)methacrylamide copolymers as potential drug carriers. 1. Pinocytosis by rat visceral yolk sacs and rat intestine cultured in vitro. Effect of molecular weight on uptake and intracellular degradation
194. w) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats
195. Delivery of antisense oligonucleotides using HPMA polymer; synthesis of a thiol polymer and its conjugation to water-soluble molecules
196. Polymers for the sustained release of proteins and other macromolecules
197. Polymers for the controlled release of macromolecules; effect of molecular weight of ethylene-vinyl acetate copolymer
198. Controlled and modulated release of basic fibroblast growth factor
199. Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery
200. Beta-cyclodextrin derivatives as carriers to enhance the antiviral activity of an antisense oligonucleotide directed toward a coronavirus intergenic consensus sequence
201. Polymer-cell surface interactions and drug targeting
202. Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon
203. Local delivery of c-myb antisense oligonucleotides during balloon angioplasty
204. Electrically conductive polymers
205. Conducting polymers (self-acid-doped, conjugated)
206. Conductive elastomeric blends
207. Preparation of a DNA matrix via an electrochemically directed copolymerization of pyrrole and oligonucleotides bearing a pyrrole group
208. Electrochemically directed copolymerization of pyrrole and oligonucleotides
209. Electrochemical method for entrapment of oligonucleotides in polymer-coated electrodes